agn-242428
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 15, 2017 (NCT03339999)
Timeline
Indications
Mechanism of action
- Nuclear receptor ROR-gammaINHIBITOR
RORC inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04030962 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2019 | Allergan |
| NCT03339999 | Phase 2 | Nov 15, 2017 | Allergan, Allergan PLC (2015) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 2 | 1 | 1 | 2017 |
| Allergan PLC (2015) | For profit | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1